Your session is about to expire
← Back to Search
Dermal Filler
Restylane-L® Lyft for Cosmetic Procedures
Phase 4
Waitlist Available
Led By Ivona Percec, MD,PhD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Female patients 40 - 65 years of age
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up upto 90 days
Awards & highlights
Study Summary
This trial will compare different types of dermal fillers to see which is best for treating age-related aesthetic changes.
Who is the study for?
This trial is for women aged 40-65 seeking cosmetic procedures to address age-related facial changes. It's not suitable for those with congenital facial asymmetry, pregnancy, previous facial rejuvenation surgeries or treatments within the last year, facial paralysis, or on blood thinners.Check my eligibility
What is being tested?
The study compares three dermal fillers: Restylane Silk®, Restylane-L®, and Restylane-L® Lyft. The goal is to assess their effectiveness in treating aesthetic changes due to aging through both numerical data and patient feedback.See study design
What are the potential side effects?
Possible side effects from the dermal fillers include redness, swelling at injection sites, bruising, pain or tenderness, itching around the area treated. These are typically temporary but can vary based on individual reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a woman aged between 40 and 65.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ upto 90 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~upto 90 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Patient Satisfaction with validated FACE-Q survey
Secondary outcome measures
Correlate patient satisfaction with volumetric measurements
Volumetric changes of treatment
Side effects data
From undefined Phase 3 trial • 332 Patients • NCT012403821%
Eye irritation
1%
Gastrointestinal bleeding
100%
80%
60%
40%
20%
0%
Study treatment Arm
0.1% HA
3% DE-089
Trial Design
1Treatment groups
Experimental Treatment
Group I: Restylane-L®, Restylane-L® Lyft, and Restylane Silk®Experimental Treatment3 Interventions
Hyaluronic acid
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Restylane-L®
2013
N/A
~850
Find a Location
Who is running the clinical trial?
University of PennsylvaniaLead Sponsor
2,000 Previous Clinical Trials
42,879,987 Total Patients Enrolled
Galderma R&DIndustry Sponsor
298 Previous Clinical Trials
60,217 Total Patients Enrolled
Ivona Percec, MD,PhDPrincipal InvestigatorUniversity of Pennsylvania Health System
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
Virginia
Colorado
New Jersey
Other
How old are they?
18 - 65
What site did they apply to?
University of Pennsylvania Health System
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0
Why did patients apply to this trial?
To learn more about the product, help further medical studies and improve my skin.
PatientReceived 2+ prior treatments
How responsive is this trial?
Typically responds via
Email
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger